![]() The latest study was conducted during India's second COVID-19 surge and in healthcare workers who were primarily offered Covaxin. ![]() The World Health Organization (WHO) added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month. In January this year, Covaxin was approved for emergency use in India for people aged 18 and above. Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed COVID-19 cases.Ĭovaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune, is an inactivated whole virus vaccine administered in a two-dose regimen, 28 days apart. ![]() The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15-May 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |